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Abstract. 
 
We describe a physiologically significant 
mechanism through which interleukin-6 (IL-6) and a 
 
rising ambient Ca
 
2
 
1
 
 interact to regulate osteoclastic 
bone resorption. VOXEL-based confocal microscopy 
of nonpermeabilized osteoclasts incubated with anti–
IL-6 receptor antibodies revealed intense, strictly pe-
ripheral plasma membrane fluorescence. IL-6 receptor 
 
expression in single osteoclasts was confirmed by in situ
 
 
 
reverse transcriptase PCR histochemistry. IL-6 (5 ng/l 
 
to 10 
 
m
 
g/l), but not IL-11 (10 and 100 
 
m
 
g/l), reversed the 
inhibition of osteoclastic bone resorption induced by 
high extracellular Ca
 
2
 
1
 
 (15 mM). The IL-6 effect was 
abrogated by excess soluble IL-6 receptor (500 
 
m
 
g/l). 
Additionally, IL-6 (5 pg/l to 10 
 
m
 
g/l) inhibited cytosolic 
Ca
 
2
 
1
 
 signals triggered by high Ca
 
2
 
1
 
 or Ni
 
2
 
1
 
. In separate 
experiments, osteoclasts incubated in 10 mM Ca
 
2
 
1
 
 or 
on bone released more IL-6 than those in 1.25 mM 
Ca
 
2
 
1
 
. Furthermore, IL-6 mRNA histostaining was 
more intense in osteoclasts in 10 or 20 mM Ca
 
2
 
1
 
 than 
cells in 1.25 mM Ca
 
2
 
1
 
. Similarly, IL-6 receptor mRNA 
histostaining was increased in osteoclasts incubated in 5 
or 10 mM Ca
 
2
 
1
 
. Thus, while high Ca
 
2
 
1
 
 enhances IL-6 
secretion, the released IL-6 attenuates Ca
 
2
 
1
 
 sensing 
and reverses inhibition of resorption by Ca
 
2
 
1
 
. Such an 
autocrine–paracrine loop may sustain osteoclastic ac-
tivity in the face of an inhibitory Ca
 
2
 
1
 
 level generated 
locally during resorption.
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I
 
nterleukin-6
 
 (IL-6)
 
1
 
 has a role in bodily functions as
critical as hematopoiesis, immune regulation, neo-
plastic transformation, bone metabolism, reproduc-
tion, arthritis, and aging. The cytokine interacts with an
80-kD glycoprotein receptor that signals through a ubiqui-
tous molecule, gp130 (Manolagas and Jilka, 1995). Like
certain related cytokines, IL-6 is critical to the enhanced
osteoclastogenesis and bone resorption that follows ova-
riectomy (Jilka et al., 1992; Tamura et al., 1993; Manolagas
and Jilka, 1995). In addition, it is known that, by interact-
ing with the NF
 
k
 
B site, estrogen regulates IL-6 gene tran-
scription directly (Kurebayashi et al., 1997). IL-6 has also
been shown to prevent osteoclast apoptosis (Hughes et al.,
1995). Finally, IL-6 promotes a maturer osteoblast pheno-
type through the Janus signal transducer and activator of
transcription (STAT) pathway (Bellido et al., 1997).
Osteoclast-like cells from giant cell tumors of bone can
themselves synthesize and secrete IL-6 (Ohsaki et al.,
1992). In addition, IL-6 stimulates pit formation by rat and
human osteoclasts (Ishimi et al., 1990; Ohsaki et al., 1992).
It has even been speculated that parathyroid hormone acts
through the rapid stimulation of osteoblastic IL-6 gene ex-
pression, whereby the released cytokine stimulates resorp-
tion (Greenfield et al., 1996). Furthermore, the osteolysis
characteristic of multiple myeloma, Paget’s disease of
bone, and the rare Gorham-Stout’s disease appears to re-
sult not only from IL-6 stimulation of osteoclastogenesis
but also from an increase in the activity of existing osteo-
clasts (Roodman et al., 1992; Delvin et al., 1996). Thus,
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while a direct effect of IL-6 on mature osteoclasts has ap-
peared plausible, molecular insights have largely been
lacking.
Mature osteoclasts are inhibited by the calcitonin, pros-
taglandins, nitric oxide, and calcium ions (Ca
 
2
 
1
 
) (Malga-
roli et al., 1989; Zaidi et al., 1989, 1994; MacIntyre et al.,
1991; Adebanjo et al., 1994). During resorption, Ca
 
2
 
1
 
 lev-
els rise to millimolar levels within the resorptive hemivac-
uole (Silver et al., 1988). This rising Ca
 
2
 
1
 
 concentration is
“sensed” by the osteoclast through a surface Ca
 
2
 
1
 
 receptor
that, we believe, is a functional component of the surface-
expressed ryanodine receptor (Zaidi et al., 1995). Ca
 
2
 
1
 
 re-
ceptor activation results in both transmembrane Ca
 
2
 
1
 
 in-
flux and intracellular Ca
 
2
 
1
 
 release (Shankar et al., 1992;
Zaidi et al., 1993
 
c
 
). The resulting cytosolic Ca
 
2
 
1
 
 increase in-
hibits osteoclast attachment, proteolytic enzyme release, and
bone resorption (Malgaroli et al., 1989; Moonga et al., 1990;
Zaidi et al., 1993
 
b
 
). There is also a direct and highly signif-
icant correlation between cytosolic Ca
 
2
 
1
 
 and resorption
inhibition (Zaidi et al., 1989, 1990; Moonga et al., 1991).
In the present study, we have attempted to explore po-
tential interactions between extracellular Ca
 
2
 
1
 
 and IL-6 in
mature active osteoclasts. We find that (
 
a
 
) osteoclasts ex-
press IL-6 and IL-6 receptor (IL-6R); (
 
b
 
) IL-6 reverses
Ca
 
2
 
1
 
-induced resorption inhibition and attenuates Ca
 
2
 
1
 
sensing; and (
 
c
 
) high Ca
 
2
 
1
 
 enhances IL-6 and IL-6R gene
expression and IL-6 secretion. We therefore hypothesize
that IL-6 production increases when an osteoclast be-
comes exposed to an otherwise inhibitory Ca
 
2
 
1
 
 level dur-
ing resorption. The IL-6 so produced then sustains resorp-
tion, at least in part, by attenuating extracellular Ca
 
2
 
1
 
sensing.
 
Materials and Methods
 
Osteoclast Culture
 
Osteoclasts were obtained by curetting neonatal rat (24 to 48 h old,
Wistar) long bones into 1 ml Hepes-buffered medium 199 containing
Hanks’ salts (M199-H) (GIBCO-BRL, Grand Island, NY) and heat-inac-
tivated FBS (5% vol/vol; Sigma Chemical Co., St. Louis, MO). The result-
ing suspension was dispersed onto prewetted devitalized cortical bone
slices (4 
 
3 
 
4 mm) or 22-mm, 0-grade glass coverslips (ICN Biomedicals,
Inc., Aurora, OH). Osteoclasts readily attached to the respective substrate
within 30 min (37
 
8
 
C), and nonadherent cells were removed by rinsing
(Zaidi et al., 1992).
 
Monoclonal Anti–IL-6R Antibodies
 
We used two highly specific anti–IL-6R monoclonal antibodies, namely
MT-18 (kindly provided by Dr. T. Taga, Osaka University, Osaka, Japan)
and 15A7 (BioSource International, Inc., Camarillo, CA). MT-18 was
raised to human IL-6R that was overexpressed in IL-6R–negative murine
T cell line, CTLL-2 (Hirata et al., 1989). The antibody detects the IL-6R
specifically by immunodetection methods, cell growth studies, and 
 
125
 
I–IL-6
binding assays (Hirata et al., 1989; Taga et al., 1989; Ohsaki et al., 1992;
May et al., 1993; Narazaki et al., 1993). 15A7 is an affinity-purified mono-
clonal antibody raised to the murine IL-6R expressed in OKT4 plasmacy-
toma cells. It recognizes mouse, human, and rat IL-6R (Vink et al., 1990).
Note that at the protein level, human IL-6R (X12830) is 
 
z
 
55% homolo-
gous to rat (M58587) or mouse (X51975) IL-6R; the latter two receptors
bear 
 
z
 
95% homology (GeneBank CDS, PDB and Swissprot Databanks,
Blast Search Software).
 
Immunocytochemistry, Confocal Microscopy, and 
VOXEL Analysis
 
Osteoclasts were incubated with normal goat serum (in 10 mM PBS, 1:10,
 
pH 7.4) in multiwell dishes (15 min) and washed with HBSS (GIBCO-
BRL). The cells were either incubated with no antibody, nonimmune
mouse serum, an anti–ryanodine receptor antibody, Ab
 
34
 
 (all controls), or
with MT-18 or 15A7 (in M199-H, 1:100 vol/vol). Notably, Ab
 
34
 
, raised
against a cytosolic ryanodine receptor epitope, does not stain nonpermeabi-
lized osteoclasts (Zaidi et al., 1995). In the same experiment, IL-6R–nega-
tive osteoblastic MBA13.2 cells (Zipori et al., 1985) were also incubated
with the same antibodies. Additionally, a set of coverslips were incubated
simultaneously with soluble (truncated) human recombinant (rh) IL-6R
(
 
z
 
38 kD; R & D Systems, Minneapolis, MN), together with MT-18. After
1 h of incubation, coverslips were rinsed gently with HBSS, drained, rein-
cubated with goat anti–mouse FITC (Sigma Chemical Co.; in HBSS, 1:100,
1 h) (FITC: 
 
l
 
ex
 
 
 
5 
 
495 nm, 
 
l
 
em
 
 
 
5 
 
525 nm), washed gently, and drained.
The number of fluorescent osteoclasts was first determined in a laser
confocal scanning microscope (Leica, Inc., Deerfield, IL). To localize
staining to the osteoclast membrane, 1-
 
m
 
m-thick optical sections were ob-
tained in the cell’s coronal plane in selected experiments (Zaidi et al.,
1995). Each optical plane was then visualized by VOXEL (volume ele-
ment) image analysis, which allowed a final three-dimensional reconstruc-
tion of the cell image (VoxelView; Vital Images Inc., Fairfield, IA). Fi-
nally, trypan blue (1 mM, 961 D; Sigma Chemical Co.) was applied to
exclude significant membrane damage that could potentially allow anti-
body access into the cytosol.
 
Molecular Cytoimaging by In Situ Reverse 
Transcriptase PCR
 
Recently, the in situ reverse transcriptase (RT)-PCR method has been ap-
plied successfully to study IL-6 and IL-6R expression in osteoblasts and
bone marrow stromal cells (Lin et al., 1997). We have now examined IL-6,
IL-6R, and glyceraldehyde 3-phosphate dehydrogenase (GA3PD) expres-
sion in mature osteoclasts in response to changes in extracellular Ca
 
2
 
1
 
.
Primer sequences were as follows (Lin et al., 1997): IL-6 J03783 5
 
9
 
-primer
49–73 ATGAAGTTCCTCTCTGCAAGAGACT, 3
 
9
 
-primer 686–663
CACTAGGTTTGCCGAGTAGATCTC; IL-6R X51975 5
 
9
 
-primer 383–
404 TGTCAACGCCATCTGTGAGTGG, 3
 
9
 
-primer 1046–1025 ACTTT-
CGTACTGATCCTCGTGG; and GA3PD M32599 5
 
9
 
-primer 51–76
TGAAGGTCGGTGTGAACGGATTTGGC, 3
 
9
 
-primer 1033–1010 CAT-
GTAGGCCATGAGGTCCACCAC.
Osteoclasts were incubated on glass coverslips (22 mm, 0 grade) in me-
dium 199 with Earle’s salts (6.6 mM Na
 
2
 
CO
 
3
 
, M199-E; 6 h, 37
 
8
 
C, 5% hu-
midified CO
 
2
 
, pH
 
 
 
7.4) in the presence of different Ca
 
2
 
1
 
 concentrations
(1.25, 5, 10, or 20 mM). They were washed with M199-E, fixed with
paraformaldehyde (4%, vol/vol) in PBS (20 min, 4
 
8
 
C), and washed twice
with cold PBS. The fixed cells were treated subsequently with 0.2 N HCl
for an additional 20 min (20
 
8
 
C) and washed with diethyl pyrocarbonate
(DEPC)-water (Sigma Chemical Co.). The cells were then treated with
proteinase-K (5 mg/l in 10 mM Tris-HCl, pH
 
 
 
8.0; 15 min, 37
 
8
 
C) and cold
paraformaldehyde (4% vol/vol; 30 min, 4
 
8
 
C). They were next dehydrated
by immersing coverslips, for 1 min each time in aqueous ethanol solutions
70, 80, 90, and 100% (vol/vol) and were subsequently air-dried. Osteoclasts
were then incubated overnight (37
 
8
 
C) with RNase-free, DNase I (1,500 U/ml;
Boehringer Mannheim Corp., Indianapolis, IN) to remove genomic DNA.
DNase I was washed out with DEPC-water and heat-inactivated (90
 
8
 
C)
for 10 min. First-strand cDNA was next synthesized by incubating cover-
slips with RT mixture (50 
 
m
 
l) composed of 1 mM dNTP, 0.01 M DTT, 400
nM gene-specific antisense (3
 
9
 
-end) primer (above), DEPC-water, and 14
U/ml Superscript RT II (GIBCO-BRL) (42
 
8
 
C, 60 min). For PCR amplifi-
cation of the synthesized DNA, the samples were treated separately with
PCR mixture (50 
 
m
 
l) composed of 0.2 mM dNTP, PCR buffer, 2.5 mM
MgCl
 
2
 
, 0.1 U/
 
m
 
l Taq polymerase, 400 nM sense (5
 
9
 
-end) and antisense (3
 
9
 
-
end) primers, 10 
 
m
 
M digoxigenin (DIG)-labeled-11-dUTP (Boehringer
Mannheim Corp.), and DEPC-water. Each sample was then covered
gently with an AmpliCover disc ensuring the absence of air bubbles. The
GeneAmp In situ PCR System 1000 (Perkin Elmer Corp., Norwalk, CT)
was programmed as follows: 4-min soak (94
 
8
 
C) followed by 40 cycles each
of 94
 
8
 
C/1 min, 65
 
8
 
C/2 min, and 72
 
8
 
C/3 min.
Incorporated DIG-11-dUTP in the PCR product was detected by an
alkaline phosphatase–conjugated anti-DIG antiserum and alkaline phos-
phatase substrates, 4-nitroblue tetrazolium chloride and 5-bromo-4-
chloro-3-indoyl-phosphate, using a DIG Nucleic Acid Detection Kit
(Boehringer Mannheim Corp.) as per
 
 
 
manufacturer’s protocol. To illus-
trate successful removal of genomic DNA by DNase treatment, we ex-
cluded the specific primers. We also ran controls that omitted the DNase
step (method validated as described; Lin et al., 1997). 
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The purple-brown staining in randomly selected cells (up to 25 cells per
variable) was quantitated by image analysis (SAMBA International Inc.,
Chantilly, VA). In each experiment, the background staining intensity was
assessed from cells that were not incubated with primer. Staining intensity
was expressed as arbitary units per unit cell area (corrected staining inten-
sity [CSI]). The mean CSI was compared for statistical differences by anal-
ysis of variance (ANOVA) and Bonferroni’s correction for inequality.
Most osteoclasts were well spread; the very few cells that were retracted
were excluded from the analysis. Although this may somewhat bias the re-
sults, it would prevent critical false-positive enhancements in staining re-
sulting from cytoplasmic condensation. Thus, although done to the best of
our ability, in situ RT-PCR quantitation is inherently fraught with inter-
pretational difficulties, and to address these issues, we studied the expres-
sion of the housekeeping gene, GA3PD.
 
Bone Resorption Assay
 
Bone resorption was measured using the pit assay of Boyde et al. (1984)
and Chambers et al. (1984), which was later modified by Dempster et al.
(1987). Once osteoclasts had sedimented (see above), the bone slices were
transferred to a multiwell dish containing medium 199 (M199-E) and 10%
(vol/vol) FBS. The following sets of experiments were performed: set A,
1.25 mM Ca
 
2
 
1
 
 (control) or 15 mM Ca
 
2
 
1
 
 with/without different concentra-
tions of rhIL-6 (5 ng/l, 0.5 
 
m
 
g/l, and 10 
 
m
 
g/l) (R & D Systems); set B, 1.25
mM Ca
 
2
 
1
 
 (control) or 15 mM Ca
 
2
 
1
 
 with/without different concentrations
of rhIL-11 (10 and 100 
 
m
 
g/l) (R & D Systems); and set C, 1.25 mM Ca
 
2
 
1
 
(control) or 15 mM Ca
 
21 with IL-6 (5 ng/l) in the presence or absence of
the soluble rhIL-6R (500 mg/l). The slices were then incubated for 24 h in
humidified CO2 (5%) (pH 5 6.9, maximal resorptive activity).
After incubation, the slices were fixed with glutaraldehyde (10%, vol/
vol) and stained for tartrate-resistant acid phosphatase (TRAP) using a
kit (Kit 386A; Sigma Chemical Co.). The number of osteoclasts with two
or more nuclei was determined on each slice using a light microscope
(Olympus, Tokyo, Japan). The cells were removed by treating the slices
with NaOCl (5 min), and the slices were rinsed with distilled water fol-
lowed by acetone and then dried. They were stained with toluidine blue
(1%, vol/vol in 1%, wt/vol borate, 5 min), and the resorption pits were
counted by light microscopy. Note that each experiment was performed
with osteoclasts obtained from three animals with five or six replicate
bone slices per treatment, and each experiment was repeated between
three and five times. The number of pits per bone slice was expressed as a
mean 6 SEM. ANOVA with Bonferroni’s correction for inequality was
used to analyze the effect of treatment (significance at P , 0.05).
Microspectrofluorimetric Measurements of
Cytosolic Ca21
Coverslips containing freshly isolated osteoclasts were incubated (30 min,
378C) with 10 mM fura-2/AM (Molecular Probes, Eugene, OR) in serum-
free medium. They were then washed in M199-H and transferred to a Per-
spex bath on the microspectrofluorimeter stage (model Diaphot; Nikon,
Telford, UK). The cells were then exposed to prewarmed M199-H con-
taining CaCl2 (10 mM) or NiCl2 (5 mM). In different experiments, osteo-
clasts were first conditioned for 3 or 4 min with IL-6 (5 pg/l to 10 mg/l) or
IL-11 (100 mg/l). The cells were then exposed alternatively to excitation
wavelengths of 340 or 380 nm every second. For recording the emitted flu-
orescence, a single osteoclast was selected by narrowing an optical dia-
phragm to approximate the cell’s boundary. The cell was then removed,
and a background count was obtained for 10 s. The average background
fluorescence (counts per second) was then subtracted automatically from
subsequent counts obtained from the selected cell. This emitted fluores-
cence was filtered at 510 nm, directed to a photomultiplier tube (model
PM28B; Thorn EMI, London, UK), and counted by a dual photon counter
(Newcastle Photometrics, Newcastle, UK). This gave a ratio of emitted in-
tensities due to excitation at 340 and 380 nm, F340/F380. Fura-2 was cali-
brated by deriving values for Rmin, Fmax, Rmax, and Fmin that were substi-
tuted into the following equation: [Ca21] 5 Kd 3 [(R 2 Rmin)/(Rmax 2 R)] 3
[(Fmax/Fmin)] (Kd 5 224 nM at 208C, 0.1 M, and pH 6.85) (Shankar et al.,
1992).
Statistical comparisons between basal and peak cytosolic Ca21 for the
Ni21-induced cytosolic Ca21 changes caused by each IL-6 concentration
were made using the paired Student’s t test. Mean changes (D) in the peak
cytosolic Ca21 level were calculated by subtracting the peak cytosolic Ca21
level from basal. At the respective IL-6 concentrations, these were com-
pared against control (cation alone) by ANOVA and Bonferroni’s correc-
tion for inequality. Finally, the rate of rise of cytosolic Ca21 was compared
by linear regression analysis.
Supernatant IL-6 Measurements by ELISA
Osteoclasts were dispersed onto either glass coverslips or cortical bone
slices (above). They were then bathed in a multiwell dish containing 500 ml
M199-E and FBS (10%, vol/vol) for up to 16 h. At each time point, nota-
bly at 0.5, 1.5, 3.5, 7.5, 15.5, and 33 h, the entire supernatant was removed
and replaced by fresh medium. Comparisons were made between three
treatment variables: 1.25 mM Ca21 on glass, 10 mM Ca21 on glass, and
1.25 mM Ca21 on bone.
IL-6 was measured using an ELISA kit (Kit M6000; R & D Systems).
In brief, 96-well plates coated with mouse IL-6 polyclonal antiserum were
used to accommodate 50 ml diluent (buffered protein) and 50 ml standard,
control, or sample. After incubation (208C, 2 h), the wells were aspirated,
washed repeatedly, and loaded with 100 ml horseradish peroxidase–conju-
gated anti–IL-6 antibody. After a further 2-h incubation (208C), 100 ml
substrate solution containing H2O2 and tetramethylbenzidine was added
to each well. Finally, a further incubation (30 min) was followed by the ad-
dition of 100 ml dilute HCl to stop the reaction. The optical density of each
sample was recorded at 450 nm on a microplate reader (Bio-Rad Labora-
tories, Hercules, CA). Immunoreactive IL-6 was estimated from the stan-
dard curve in triplicate experiments. Precision and accuracy were assessed
as per kit instructions. The accumulation and calculated rate of IL-6 re-
lease were represented as means 6 SEM, and comparisons were made us-
ing ANOVA with Bonferroni’s correction for inequality (P , 0.05).
Results
Confocal Microscopic Localization of IL-6 Receptors to 
the Osteoclast Plasma Membrane
Fig. 1, a and c, shows confocal microscopic images of os-
teoclasts stained with the anti–IL-6R antibodies, MT-18
and 15A7, respectively. The intense peripheral staining
was distinctly reminiscent of a plasma membrane pattern.
Notably, IL-6R–negative MBA13.2 cells did not stain with
either MT-18 (Fig. 1 d) or 15A7 (not shown). Fig. 1, e–g,
shows VOXEL (volume element) imaging of optical sec-
tions taken in the cell’s coronal (Fig. 1 e) or sagittal (Fig. 1
f) planes. A three-dimensional VOXEL whole-cell image
(Fig. 1 g) again confirmed a cell surface localization of the
MT-18 staining. Every one of the z100 osteoclasts exam-
ined in different experiments stained with both MT-18 and
15A7. All cells were negative for trypan blue.
Control experiments to test specificity of the antibody
staining were performed by (a) not including antibodies
MT-18 and 15A7, (b) using nonimmune mouse serum in-
stead of the antibodies, (c) using an anti–ryanodine recep-
tor antibody, Ab34, and (d) including excess soluble rhIL-6R
(500 mg/l) before and during incubation with the antibod-
ies. Note that because the soluble rhIL-6R lacks a trans-
membrane region, it should not normally incorporate into
the plasma membrane but should bind both MT-18 and
15A7. It should therefore displace the respective antibod-
ies from their binding sites on the osteoclast. MT-18 stain-
ing intensity was reduced to a very faint glow, seen in Fig.
1 b, upon incubation with soluble rhIL-6R. Furthermore,
the fact that osteoclasts did not stain with the Ab34, nonim-
mune mouse serum, or when no antibody was added (not
shown) provided further controls for specificity. Note that
Ab34 is directed to a cytosolic ryanodine receptor epitope
and does not stain the surface of nonpermeabilized osteo-
clasts (Zaidi et al., 1995).The Journal of Cell Biology, Volume 142, 1998 1350
Effect of IL-6 on the Resorptive Activity of Mature
Rat Osteoclasts
The function of the expressed osteoclast IL-6R was next
assessed in bone resorption assays. We confirmed that
Ca21 inhibited pit number per slice significantly (P 5
0.007; n 5 5 slices per experiment) in all five experiments
(Fig. 2 a). IL-6 itself, at concentrations of 5 ng/l, 0.5 mg/l,
and 10 mg/l, did not significantly enhance resorption (P 5
0.205,  0.126, and 0.48, respectively; n 5 10 slices/con-
centration, up to five experiments). However, at all three
concentrations, IL-6 reversed the resorption inhibition in-
duced by Ca21 (Fig. 2 a). Thus, when IL-6 was applied to-
gether with Ca21, the pit number per slice was significantly
different from that on the Ca21-treated slices (P 5 0.002,
0.026, and 0.05, respectively, for the three IL-6 concentra-
tions; n 5 10) (Fig. 2 a). The number of TRAP-positive
multinucleated cells did not change with any of the above
treatments.
We used the related cytokine, IL-11, at two concentra-
tions (10 and 100 mg/l). Note that IL-11 and IL-6 are
known to trigger intracellular signaling by binding to the
same transducer, gp130. However, IL-11, even at a rela-
tively high concentration, failed to reverse Ca21-induced
resorption inhibition (Fig. 2 b). Thus, the significant inhi-
bition of resorption seen with Ca21 ( P  ,  0.001, n 5 5
slices) still persisted despite IL-11 application (P , 0.001,
for both concentrations compared with control; n 5 5
slices) (Fig. 2 b).
Finally, we used the soluble rhIL-6R in competition ex-
periments. As explained above, soluble IL-6R is expected
to displace IL-6 from its surface-binding sites. Likewise, we
found that soluble rhIL-6R (500 mg/l) reversed the effect
of IL-6 (5 ng/l) in attenuating the resorption inhibition in-
duced by 15 mM Ca21 (Fig. 2 c). Thus, there was no signif-
icant difference (P 5 0.733; n 5 5 slices) between resorp-
tion by osteoclasts treated with Ca21 alone and those
treated with Ca21, IL-6, and soluble rhIL-6R. As expected,
soluble rhIL-6R did not itself significantly affect bone re-
Figure 1. Confocal micro-
scopic localization of the IL-
6R on rat osteoclast plasma
membrane. (a and c) Intense
peripheral immunofluores-
cent staining of osteoclasts
with two highly specific anti–
IL-6R monoclonal antibod-
ies, MT-18 (a; serial sections
in coronal plane, 1 mm thick)
and 15A7 (c; single coronal
section). Note that osteo-
clasts incubated with no anti-
serum, nonimmune mouse
serum, or an irrelevant anti-
body (Ab34) did not stain
(not shown). (b) Very faint
staining of an osteoclast with
MT-18 coincubated with sol-
uble rhIL-6R (500 mg/l); this
confirms IL-6R specificity of
the antibody. (d) Lack of ap-
preciable staining of IL-6R–
negative MBA13.2 cells incu-
bated with antibody, MT-18.
For details on confocal mi-
croscopy, see Materials and
Methods. (e and f) VOXEL
(volume element) imaging of
osteoclasts stained with the
anti–IL-6R antibody, MT-18.
This method allows three-
dimensional optical section-
ing in both the coronal (e)
and sagittal (f) planes of the
cell. Staining is typically lo-
calized to the cell’s periphery
with a sparing of the central
cytoplasmic and nuclear ar-
eas. (g) A three-dimensional
reconstruction of membrane
staining from the coronal and
sagittal sections.Adebanjo et al. Osteoclast Regulation by IL-6 1351
sorption (cf., control, P 5 0.536, n 5 5 slices), while IL-6
alone abolished the Ca21 effect (cf., Ca21 alone, P 5 0.001,
n 5 5 slices) (Fig. 2 c). Taken together, the results suggest
strongly that the attenuation of Ca21-induced resorption
inhibition is highly specific to IL-6 and appears not to be
shared by related cytokines, such as IL-11.
Effect of IL-6 on Extracellular Ca21 (Cation) Sensing 
by Isolated Osteoclasts
We measured cytosolic Ca21 levels in fura-2–loaded osteo-
clasts that were exposed to IL-6 (5 ng/l, 0.5 mg/l, 5 mg/l, or
10 mg/l) and 10 mM Ca21. In separate experiments, osteo-
clasts were preincubated for between 3 and 4 min, with a
range of IL-6 concentrations (5 pg/l to 10 mg/l) or with 100
mg/l IL-11, and then exposed to 5 mM Ni21. Of note is that
activation of the Ca21 receptor by Ni21 triggers intracellu-
lar Ca21 release selectively (Caputo, 1981; Shankar et al.,
1992). In contrast, an elevated extracellular Ca21 triggers
both Ca21 release and Ca21 influx, resulting in a rapid rise
of cytosolic Ca21 followed by its sustained elevation (Zaidi
et al., 1993a).
Figure 2.( a ) Bone resorption by isolated rat osteoclasts, ex-
pressed as the mean pit number per bone slice (6SEM), in the
presence of different concentrations of IL-6 and CaCl2 (Ca21), as
shown. Statistics by ANOVA with Bonferroni’s correction for in-
equality. Compared with control: aP 5 0.205, bP 5 0.126, cP 5
0.418, and dP 5 0.007; compared with 15 mM Ca21: eP 5 0.002,
fP 5 0.026, and gP 5 0.05. (b) Bone resorption by isolated rat os-
teoclasts, expressed as the mean pit number per bone slice
(6SEM), in the presence of different concentrations of IL-11 and
CaCl2 (Ca21), as shown. Statistics by ANOVA with Bonferroni’s
correction for inequality. Compared with control: aP 5 0.621, bP 5
0.317, and c–eP , 0.001. (c) Bone resorption by isolated rat osteo-
clasts, expressed as the mean pit number per bone slice (6SEM)
in the presence of different concentrations of CaCl2 (Ca21), IL-6,
and/or the soluble rhIL-6R, as shown. Statistics by ANOVA with
Bonferroni’s correction for inequality. Compared with control:
aP 5 0.847, bP 5 0.536, c,e,fP , 0.001, and dP 5 0.675.
Figure 3. Representative traces showing the effect of IL-6 on cy-
tosolic Ca21 levels elicited in fura-2–loaded rat osteoclasts in re-
sponse to 10 mM Ca21 applied extracellularly with either vehicle
or 0.5, 5, or 10 mg/l IL-6 (n 5 4–6 cells for each variable). For sta-
tistical analysis, see Table I.
Table I. 
Treatments Dp Ds ts
nM nM nM/s
Ca21 alone 25.6 6 6.93 652 6 19.2 0.54 6 0.02
Ca21 1 IL-6 (5ng/l) 19.8 6 4.91 44.7 6 8.36* 0.39 6 0.07
Ca21 1 IL-6 (0.5 mg/l) 0.05* 12.5 6 3.10* 0.23 6 0.11
Ca21 1 IL-6 (5 mg/l) 0.6* 5.71 6 1.55* 0.17 6 0.05‡
Ca21 1 IL-6 (10 mg/l) 0 28.3 6 24.5* 0.15 6 0.01‡
The effect of IL-6 on the primary and secondary cytosolic Ca21 responses elicited by
10 mM Ca21 applied extracellularly. The mean change (D) (6SEM) cytosolic Ca21
was calculated from the difference between basal and either peak (Dp at 100 s, for the
primary response) or plateau (Ds at 500 s, for the secondary response). The rate of
change of cytosolic Ca21 (ts) was calculated from the slope of the slowly rising phase
of the secondary response. Significant differences: Dp and Ds compared with control
(Ca21 alone), *P , 0.001. The ts values for 5 and 10 mg/l IL-6 were significantly
(‡P , 0.02) different from control (Ca21 alone) (n 5 4–6 cells).The Journal of Cell Biology, Volume 142, 1998 1352
We found that exposure of osteoclasts to IL-6 (5 ng/l, 0.5
mg/l, 5 mg/l, and 10 mg/l) resulted in no change in cytosolic
Ca21 for up to 10 min. As expected, application of 10 mM
Ca21 alone triggered a rapid, approximately fivefold eleva-
tion in cytosolic Ca21 resulting from Ca21 release (“pri-
mary” response); this was followed by a slow Ca21 influx
(“secondary” response) (Fig. 3). IL-6 attenuated (a) the
primary Ca21-induced Ca21 release response (Dp, Table I)
at 0.5 mg/l and above, and (b) the secondary, more pro-
longed Ca21 influx response (Ds, Table I) at a lower
concentration (5 ng/l). Note that complete reversal of
Ca21-induced resorption inhibition occurs at IL-6 concen-
trations as low as 5 ng/l (cf., Fig. 2 a).
We next attempted to characterize further the IL-6 ef-
fect on Ca21 (cation) sensing by using Ni21. Application of
Ni21, at a concentration of 5 mM, resulted (as previously)
in a rapid rise of cytosolic Ca21 to a peak within 50 s, fol-
lowed by an exponential decay to near-basal levels within
150 s. Preincubation of osteoclasts with IL-6 (between 5
pg/l and 10 mg/l) resulted in a progressively diminishing
Ni21-induced cytosolic Ca21 signal; this attenuation was
significant at 50 ng/l IL-6 (P 5 0.035), and complete abro-
gation occurred at 10 mg/l (Fig. 4, Table II). Table II pre-
sents a comparison of the magnitudes of the Ni21-induced
cytosolic Ca21 response at each IL-6 concentration. Note
that the related cytokine, IL-11, used at 100 mg/l did not
attenuate Ni21-induced cytosolic Ca21 elevation, suggest-
ing that this action was specific to IL-6. Taken together,
the results with Ca21 and Ni21 indicate that extracellu-
lar Ca21 (cation) sensing by the osteoclast is inhibited
strongly by IL-6 but not by the related cytokine, IL-11.
Effect of Ca21 on IL-6 Production in
Osteoclast Cultures
Osteoclasts were incubated in M199-E either on glass cov-
erslips (1.25 or 10 mM Ca21) or on bone slices (1.25 mM
Ca21). The supernatant was decanted at 0.5, 1.5, 3.5, 7.5,
15.5, and 33 h, and an equal volume of fresh medium was
replaced. Estimates of the cumulative IL-6 concentration
and release rate were obtained for each time point. It
should be noted that other contaminating cells in our cul-
tures might contribute to the measured IL-6. Fig. 5 a
shows that for all three treatment variables, the mean cu-
Figure 4. Representative traces showing the effect of preincubation with either IL-6 (5 pg/l to 10 mg/l) or IL-11 (100 mg/l) on cytosolic
Ca21 levels in fura-2–loaded rat osteoclasts elicited in response to the application of 5 mM Ni21 extracellularly (n 5 4–6 cells for each
variable). For statistical analysis, see Table II.
Table II. 
Treatments Pretreatment Peak Posttreatment D
Ni21 5 mM alone 117 6 3.87 636 6 50.7* 144 6 8.25 519 6 40.8
IL-11 (100 mg/l) then Ni21 72.0 6 10.5 545 6 245 57.9 6 9.87 473 6 255‡
IL-6 (5 pg/l) then Ni21 139 6 26.3 618 6 126* 184 6 78.3 477 6 120§
IL-6 (5 ng/l) then Ni21 123 6 14.4 552 6 135* 128 6 23.0 429 6 131i
IL-6 (50 ng/l) then Ni21 87.9 6 15.4 268 6 124 127 6 30.0 180 6 111¶
IL-6 (0.5 mg/l) then Ni21 82.5 6 6.0 257 6 30.9* 82.5 6 6.0 176 6 24.8**
IL-6 (5 mg/l) then Ni21 96.3 6 28.0 161 6 28.9 88.9 6 16.4 64.2 6 39.6**
IL-6 (10 mg/l) then Ni21 122 6 27.8 138 6 36.0 105 6 19.4 16.3 6 12.6**
The effect of IL-6 and IL-11 on the magnitude of cytosolic Ca21 transients elicited in response to the application of 5 mM Ni21. The table displays values of cytosolic Ca21 (nM,
6SEM, n 5 4–6 cells) computed before (Pretreatment), during (Peak), and after (Posttreatment) application of 5 mM Ni21. The change (D) in cytosolic Ca21 (6SEM) is also
shown. The latter has been calculated from the difference between the peak and pretreatment values. Statistics by ANOVA comparing each mean pretreatment value with the re-
spective peak value (*P , 0.05). The cytosolic D Ca21 of the IL-6 (or IL-11) pretreated groups were similarly compared with Ni21 alone: ‡P 5 0.22, §P 5 0.75, iP 5 0.53, ¶P 5
0.035, and **P 5 0.001.Adebanjo et al. Osteoclast Regulation by IL-6 1353
mulative IL-6 concentration steadily increased to .20-fold
above basal at 33 h. Mean levels for the three treatment
variables, at each time point, followed the rank order 10
mM Ca21 on glass . 1.25 mM Ca21 on bone . 1.25 mM
Ca21 on glass (control). ANOVA revealed that the mean
IL-6 concentration for the 10 mM Ca21 on glass prepara-
tion was significantly higher (P values, legend to Fig. 5)
than that for the control preparation at all time points up
to 930 min. The 1.25 mM Ca21 on bone preparation dif-
fered from control only at 30 min (143 6 36 vs. 21.8 6 5.52
ng/l; P 5 0.05) and 930 min (1815 6 45.7 vs. 763 6 61.5 ng/l;
P 5 0.005). At 33 h, none of the variables were signifi-
cantly different from each other.
IL-6 release rate was calculated as the concentration per
unit time. Fig. 5 b shows that this was almost constant over
the 33 h for the 1.25 mM Ca21 on glass preparation (con-
trol). With the 10 mM Ca21 on glass treatment variable,
there was an initial, highly significant, greater than fivefold
rise in IL-6 release within 30 min; the calculated rate then
fell to basal within 450 min, at which point the release rate
was not significantly different from control (Fig. 5 c). In
contrast, for the 1.25 mM Ca21 on bone, the release rate
showed a similar rise to approximately fivefold within 30
min, fell sharply within 90 min to near-control levels, but
then displayed a secondary rise at 930 min. At 33 h, the re-
lease rate again fell to a level not significantly different
from control (Fig. 5 d).
Effect of Ca21 on IL-6 and IL-6R mRNA Levels in 
Single Osteoclasts
The fact that IL-6 secretion from mature osteoclasts ap-
peared to be Ca21 sensitive prompted us to examine the
effects of extracellular Ca21 on IL-6 and IL-6R gene ex-
pression in single osteoclasts. Messenger RNA for IL-6,
IL-6R, and GA3PD genes was detected by identifying the
purple-brown cytoplasmic staining (see Materials and
Methods). The cells remained colorless when RT-PCR
was performed without added primer (Fig. 6, Control).
Typically, IL-6 mRNA staining was enhanced in cells pre-
incubated with high Ca21. The mean CSI (see Materials
and Methods) for osteoclasts incubated in 10 or 20 mM
Ca21 (mean 6 SEM, arbitary units, 58.6 6 7.68 and 66.1 6
8.58, respectively) was significantly (P , 0.001 for both
cases, n 5 10) higher than that of cells incubated in 1.25
mM Ca21 (27.3 6 1.81). Additionally, a frequency histo-
gram showed that the control osteoclast CSIs were signifi-
cantly skewed to the left compared with the CSIs of cells
incubated in 10 mM Ca21 (Fig. 7 a). The stimulatory effect
of Ca21 on IL-6 gene expression thus appeared consistent
with the cation’s effect on IL-6 secretion.
Similar results were obtained with the IL-6R gene. The
mean CSI at 5 and 10 mM Ca21 (18.1 6 1.42 and 18.6 6
1.74, respectively) were significantly (P , 0.001 for both
cases, n 5 6–21) elevated compared with 1.25 mM Ca21
(8.32 6 0.43). However, there was a significant decline in
mean CSI at 20 mM Ca21 (10.0 6 1.66, n 5 6), so that it
was not significantly different from that in 1.25 mM Ca21
(P 5 0.18). Furthermore, intensely stained osteoclasts pre-
dominated in the frequency plot in the 5 mM Ca21 group
compared with the 1.25 mM Ca21 group (Fig. 7 b). Taken
together, the results suggest that extracellular Ca21 not
only enhanced the synthesis and secretion of IL-6 but also
enhanced the synthesis of its receptor.
Finally, as high Ca21 levels may induce osteoclastic
shape changes that could, in turn, introduce artifacts in our
Figure 5.( a ) Cumulative su-
pernatant levels of IL-6 (mg/l)
after incubation of disag-
gregated osteoclast cultures
with either 1.25 mM Ca21
(squares) or 10 mM Ca21 (cir-
cles) (on glass coverslips) or
on bone slices (Ca21 5 1.25
mM) (triangles). Statistics by
ANOVA and Bonferroni’s
correction for inequality:
a,b,cP  5  0.001,  dP  5  0.05,  eP  5
0.0021,  fP  5  0.47,  gP  5  0.05,
hP  5  0.217,  iP  5  0.13,  jP  5
0.064,  kP  5  0.005, and lP 5
0.683, all compared with the
corresponding time points
for the 1.25 mM Ca21 (on
glass) variable. (b–d) IL-6 re-
lease rates (ng l21 min21) af-
ter incubation of disaggre-
gated osteoclast cultures with
either 1.25 mM Ca21 ( b ,
squares) or 10 mM Ca21 ( c ,
circles) (on glass coverslips)
or on bone slices (Ca21 5 1.25
mM) (d, triangles). Statistics
by ANOVA and Bonferroni’s
correction for inequality: aP 5 0.05, bP 5 0.028, cP 5 0.006, dP 5 0.740, eP 5 0.001, fP 5 0.849, gP 5 0.087, and hP 5 0.092. Note that
other contaminating cells in our cultures may contribute to the measured IL-6.The Journal of Cell Biology, Volume 142, 1998 1354
densitometric staining evaluation, we studied the expres-
sion of the housekeeping gene, GA3PD. We expected its
expression to be invariant regardless of whether the extra-
cellular Ca21 levels were high or low. This was indeed the
case, suggesting that even subtle shape changes were un-
likely to affect our densitometry results to any significant
extent.
Discussion
Microelectrode studies have revealed that during each epi-
sode of bone resorption, the Ca21 concentration within a
resorptive hemivacuole rises to between 8 and 40 mM (Sil-
ver et al., 1988). In vitro experiments have demonstrated
that such high extracellular Ca21 levels inhibit osteoclastic
resorption (for review see Zaidi et al., 1993b). Notably, a
change in the cell’s ambient Ca21 level is sensed by a sur-
face membrane Ca21 receptor (Zaidi et al., 1995). Several
morphological and biochemical changes ensue, including
reductions in cell attachment, spreading, enzyme release,
and acid secretion (Malgaroli et al., 1989; Moonga et al.,
1990; Zaidi et al., 1993b). We believe that these inhibitory
responses to high Ca21 are mediated through Ca21 influx
via a surface ryanodine receptor (Zaidi et al., 1993a, 1995).
Should these changes persist, however, bone resorption
would be self-limiting. It is of paramount physiological im-
portance, therefore, to have in place a mechanism for re-
establishing resorption after its inhibition by resorbed
Ca21.
It is evident from our study that IL-6, by interacting with
its receptor, reverses the inhibitory effect of Ca21 on bone
resorption. This reversal correlates with the attenuation,
by IL-6, of (a) the primary cation-induced Ca21 release re-
sponse at 0.5 mg/l and above, and (b) the secondary, more
prolonged, Ca21 influx response at a lower concentration
of 5 ng/l. Indeed, Ca21-induced resorption inhibition is re-
versed at 5 ng/l IL-6. Furthermore, the secondary phase, as
opposed to the primary response, is thought to mediate
the long-term effects of Ca21 on resorption (Zaidi et al.,
1989). Thus, attenuation of the secondary rise in cytosolic
Ca21 by IL-6 may contribute, in part, to the reversal of the
antiresorptive effect of Ca21 over the 24-h incubation.
Nevertheless, alternate signaling pathways may also be
used by IL-6.
It is of note that the closely related cytokine, IL-11, does
not mimic the IL-6 effect, although IL-11 receptors appar-
ently exist on osteoclast-like cells (Bellido et al., 1996).
This important difference, which establishes the specificity
of IL-6 action, is even more striking because the two cy-
tokines, IL-6 and IL-11, share a common transduction
pathway. Their distinct a receptor subunits heterodimer-
ize with a common glycoprotein, gp130, to activate several
kinases, including the JAK/STAT and MAPK pathways
(Hilton et al., 1994; Bellido et al., 1996). It is not known,
Figure 6. Histostained osteoclasts after in situ RT-PCR for detection of either IL-6 mRNA, IL-6R receptor mRNA, or GA3PD mRNA.
The left panels represent controls, i.e., without added primer. For details and primer sequences, refer to Materials and Methods.Adebanjo et al. Osteoclast Regulation by IL-6 1355
however, which kinase pathway is used by IL-6 to antago-
nize the Ca21-induced resorption inhibition. However, as
IL-6 abrogates both Ca21 influx and Ca21 release, we sug-
gest that the cytokine acts proximally. As with calcitonin
(Zaidi et al., 1996), the Ca21 receptor could itself become
inactivated via IL-6–induced phosphorylation.
We next examined whether extracellular Ca21 modu-
lates IL-6 expression in, and secretion from, the osteoclast.
Immunoreactive IL-6 levels in control cultures increased
to z20-fold above basal during the 33-h incubation, indi-
cating constitutive IL-6 expression. Furthermore, a rapid
induction in IL-6 secretion followed the elevation of extra-
cellular Ca21 from 1.25 mM to 10 mM. In contrast, when
osteoclasts were resorbing bone, a rapidly rising phase of
IL-6 secretion was followed by a more delayed elevation
around 7.5 and 15.5 h. The enhanced secretion of pre-
formed IL-6 could conceivably explain the initial eleva-
tions of IL-6. An effect of Ca21 on IL-6 gene transcription
nevertheless remains a plausible explanation. It should be
noted, however, that other contaminating cells in our cul-
tures might contribute to the measured IL-6.
Finally, we investigated the effect of Ca21 on IL-6 gene
expression by incubating osteoclasts for 6 h in the pres-
ence of elevated Ca21 levels (5, 10, and 20 mM). A marked
enhancement of IL-6 mRNA expression was noted in cells
incubated with 10 and 20 mM Ca21 compared with those
incubated with 1.25 mM Ca21. These results may have
been confounded by the subtle changes in osteoclast shape
induced upon Ca21 exposure that may have affected densi-
tometric staining measurements. However, we found that
the expression of a housekeeping gene, GA3PD, did not
change under the same experimental conditions. Nonethe-
less, these results should be treated with caution because
of the inherent variability of in situ PCR methodology as
well as the densitometric methods used for quantitation.
Although the effect of Ca21 on IL-6 secretion and syn-
thesis appears dramatic, its mechanism remains poorly un-
derstood. It is known that Ca21 can regulate transcription
of the IL-6 gene promoter (Franchimont et al., 1997).
However, it still remains unclear whether Ca21 interacts
directly with a Ca21-response element on the promoter, or
whether it acts indirectly via protein kinase C (Shen et al.,
1988; Rosen et al., 1995). Furthermore, it is interesting that
IL-6R mRNA is elevated in osteoclasts incubated in high
Ca21. Indeed, that the synthesis of a cytokine and its re-
ceptor should rise in parallel makes good physiological
sense.
Although our results appear to be relevant physiologi-
cally, we have no information on the concentration of IL-6
released in situ. The cumulative levels of IL-6 in our cul-
tures, however, do match those required for attenuating
Ca21 (cation) sensing and for reversing Ca21-induced re-
sorption inhibition. It is a paradox then that exogenous but
not endogenous IL-6 abrogates the effect of a high Ca21
level. However, in our in vitro pit assay, osteoclasts are ex-
posed to Ca21 during the early phases of resorption and
thus become inhibited well before the enhanced IL-6 syn-
thesis and release results in IL-6 accumulation. Further-
more, high extracellular Ca21 will enhance IL-6 secretion
only until IL-6 levels rise high enough to inhibit Ca21 sens-
ing. In experiments wherein IL-6 is added together with
Ca21, it is expected that IL-6 would reverse any acute in-
hibitory effects of the cation, presumably from the initia-
tion of even the first resorptive episode. In addition, IL-6
is known to enhance the transcription of its own gene and,
at least hypothetically, this should lead to higher cumula-
tive IL-6 levels.
In conclusion, it is conceivable that the Ca21 generated
during normal resorption, which would otherwise inhibit
osteoclast activity, enhances IL-6 and IL-6R expression.
The secreted IL-6 should then, through a negative auto-
crine loop, attenuate Ca21 sensing, and hence sustain bone
resorption even in the face of a rising Ca21 level. Note,
however, that a simple decrease in lacunar Ca21 resulting
from diffusion due to cell deadhesion and retraction would
also release an osteoclast from Ca21-induced inhibition.
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